Niagen Q3 Sales Fall 20% to $27.2M; Net Loss of $1.2M as Ingredient Business Slumps
NAGE is trading near its 52-week low of $2.31 (9.1% above the low).
Summary
Niagen reported Q3 2026 net sales of $27.2M, down 20% year-over-year, and a net loss of $1.2M as ingredient sales slumped. The company still generated $2.6M of operating cash flow and held $69.5M in cash with no debt.
Updates
· SEC 10-Q — Niagen's nine-month net income was $6.1M, including a $4.8M gain on the February sale of its Analytical Reference Standards segment for about $6.0M.
Key Events · Earnings and Guidance · NAGE
-
Q3 Sales Drop 20% Year-over-Year
Net sales were $27.2M versus $33.986M in Q3 2025, with Tru Niagen contributing $23.3M. Food-grade Niagen ingredient sales fell to $3.4M from $6.4M.
-
Quarter Swings to $1.2M Net Loss
Net loss of $1.2M, or $(0.01) per share, compared with net income of $4.578M, or $0.06 per share, a year earlier. Adjusted EBITDA was $0.5M versus $6.361M.
-
Cash Position Remains Solid
The company ended the quarter with $69.5M in cash and no outstanding borrowings, up from $66.7M at June 30, 2026, and generated $2.6M of operating cash flow in the quarter.
-
2026 Outlook: Investment Year
Management expects direct website revenue to grow 15-20% and overall e-commerce about 5% for 2026, with the ingredient business lower than the prior year and Niagen Plus and skincare becoming meaningful contributors in 2027.
Analysis · NAGE · Life Sciences
The top line is shrinking fast: Q3 net sales of $27.2M are down 20% from $33.986M a year ago, and the company swung from $4.578M of net income to a $1.2M loss. The damage is concentrated in the ingredient business, where food-grade Niagen sales fell to $3.4M from $6.4M, which management attributes to lower volume from key partners amid competitive pressure. What keeps this from being a liquidity story is the balance sheet: $69.5M of cash, no borrowings, and $2.6M of positive operating cash flow in the quarter. Management is explicitly calling 2026 an investment year and pointing to 2027 for Niagen Plus and skincare to contribute, so the near-term question is whether the consumer and e-commerce growth (direct website up 13% year-over-year) can offset the ingredient decline before the cash cushion gets tested.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAGE was trading at $2.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.4M. The 52-week trading range was $2.31 to $7.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.